Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus METASTRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus METASTRON.
CIS-MDP vs METASTRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical